Shares of Hims & Hers Health (NYSE: HIMS) plunged 23% on Friday after the U.S. Food and Drug Administration (FDA) […]
Hims & Hers Health Stock Plummets as FDA Ends Novo Nordisk Drug Shortage Read More »
Canaccord Genuity analyst Maria Ripps raised her price target for Hims & Hers Health (NYSE: HIMS) to $68.00, up from
Hims & Hers (NYSE: HIMS) Stock Gets Major Price Target Upgrade Read More »
NEW YORK – On Wednesday, Hims & Hers Health (NYSE: HIMS), the U.S. telehealth company, said it will sell compounded
Hims & Hers (NYSE: HIMS) Offers Compounded Wegovy for $99/Month to Select Professions Read More »
Copyright © 2025 abbonews.com
